Publications by authors named "Francesca Hogan"

Claim this Profile
O
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy.
Jad Othman, Angela Hwang, Maximillian Brodermann, Islam Abdallah, Kayleigh McCloskey, Francesca Hogan

Blood Adv· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS.
Jad Othman, Ho Pui Jeff Lam, Sarah Leong, Faisal Basheer, Islam Abdallah, Francesca Hogan

Blood Neoplasia· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.
Jad Othman, Ing S Tiong, Jenny O'Nions, Mike Dennis, Katya Mokretar, Francesca Hogan

Blood· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects.
Francesca L Hogan, Victoria Williams, Steven Knapper

Curr Cancer Drug Targets· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spontaneous pneumomediastinum: an important differential in acute chest pain.
Francesca Hogan, Chris McCullough, Asif Rahman

BMJ Case Rep· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis